Torray LLC has purchased Blueprint Medicines Co. (NASDAQ:BPMC) shares.
Torray LLC's holdings in Blueprint Medicines Co. (NASDAQ: BPMC), as stated in the most recent report that the company has ...
Tag: BPMC, Analyst Rating
Comerica Bank sells Blueprint Medicines Co. (NASDAQ:BPMC) stock.
The most recent 13F filing that Comerica Bank made with the Securities and Exchange Commission (SEC) revealed that during the ...
Wells Fargo & Company has upgraded Blueprint Medicines (NASDAQ:BPMC) to “Equal Weight.”
Wells Fargo & Company equity analysts published a research note to clients on Monday in which they upgraded Blueprint Medicines ...
Blueprint Medicines Co. (NASDAQ:BPMC) Receives Analysts’ Consensus Recommendation of “Hold”
According to Bloomberg.com, the twenty research firms currently analyzing the company have given the stock of Blueprint Medicines Co. (NASDAQ: ...
Wedbush forecasts Blueprint Medicines Co. (NASDAQ:BPMC) to earn ($2.57) per share in the first quarter of 2023.
On Tuesday, November 1, stock analysts from Wedbush provided customers and investors with a research note in which they published ...
Blueprint Medicines Co. (NASDAQ:BPMC) Receives Analysts’ Consensus Recommendation of “Moderate Buy”
According to Bloomberg.com, the nineteen rating agencies covering Blueprint Medicines Co. (NASDAQ: BPMC) have given the company an average "Moderate ...
Berenberg Bank initiates coverage on Blueprint Medicines (NASDAQ:BPMC).
According to The Fly, research analysts at Berenberg Bank covered Blueprint Medicines (NASDAQ: BPMC) in a note distributed to investors ...
